Browse the evidence

Intensive lifestyle intervention (ILI) focused on weight loss does not significantly reduce all-cause mortality in older adults with type 2 diabetes and overweight/obesity compared to diabetes support and education (DSE) over a median of 16.7 years.

For older adults with type 2 diabetes, engaging in intensive lifestyle programs (diet and exercise) is recommended to improve quality of life, fitness, and metabolic health, but should not be undertaken with the expectation that it will significantly extend lifespan compared to standard diabetes education. The intervention is safe and does not increase mortality risk.

Enteroendocrine cells (EECs) act as chemosensors that secrete hormones (e.g., GLP-1, PYY, CCK) in response to luminal nutrients, regulating appetite, glucose metabolism, and gut motility.

Your gut contains specialized cells that sense what you eat and send signals to your brain and pancreas to regulate hunger and blood sugar. This natural system can be targeted by medications to treat metabolic diseases.

Obesity is an independent proarrhythmic risk factor for both atrial and ventricular arrhythmias, mediated by structural remodeling (atrial/ventricular dilation, epicardial fat infiltration) and electrophysiological changes (prolonged QTc, P-wave dispersion).

Obesity directly increases the risk of heart rhythm problems (atrial and ventricular arrhythmias) through structural changes like heart enlargement and fat infiltration around the heart. This risk exists independently of other conditions like high blood pressure. Weight loss is a key intervention to reduce this risk.

Long-term weight loss maintenance is physiologically opposed by metabolic adaptation (reduced energy expenditure) and hyperphagia (increased appetite), driven by neuroendocrine signals like leptin, making weight regain the default biological state.

Understand that after weight loss, your body biologically fights to regain weight through increased hunger and slower metabolism. This is not a failure of willpower but a physiological defense. Successful maintenance requires acknowledging this biological reality and often necessitates ongoing, lifelong behavioral or medical support to counter these natural drives.

Loss-of-function mutations in the central melanocortin system (specifically MC4R, POMC, or AgRP pathways) consistently increase fat preference and decrease carbohydrate preference in both rodents and humans.

For individuals with specific genetic variants affecting the melanocortin system, there is a biological predisposition toward higher fat preference and lower carbohydrate preference. Recognizing this can help in selecting dietary strategies that align with these preferences or manage them through environmental control.

The hypothalamus regulates body fat mass through a defended set point, where afferent signals from gut hormones (GLP-1, CCK, ghrelin) and adipose tissue (leptin) modulate food intake and energy expenditure.

Your brain uses signals from your gut (like GLP-1 and ghrelin) and fat cells (leptin) to decide how hungry you are and how much energy you burn. In obesity, this system is broken, defending a higher weight.

Body Mass Index (BMI) is an inadequate and potentially misleading metric for assessing individual cardiometabolic risk because it fails to account for regional fat distribution and ectopic lipid deposition, which are the true drivers of disease.

Stop using BMI as your primary health metric. Instead, focus on waist circumference and metabolic markers (blood pressure, lipids, glucose). If you have a high BMI but a small waist and good metabolic markers, your risk may be low. Conversely, if you have a normal BMI but a large waist, your risk may be high. Prioritize lifestyle habits (diet quality, physical activity) that reduce visceral fat rather than just total weight.

Obesity is a chronic disease driven by pathophysiologic dysregulation of energy balance (neural, hormonal, metabolic pathways), not merely a behavioral failure of discipline.

Stop blaming yourself for your weight. Your body's biology (hormones, brain signals) is actively fighting weight loss. This is a medical condition, not a moral failure. Effective treatment requires addressing the biology, not just 'trying harder'.

Obesity is a chronic disease characterized by physiological dysregulation of fat mass, not merely a result of willful behavioral choices.

Stop blaming yourself for your weight. Obesity is a chronic disease driven by your body's physiology, not just your willpower. Seek medical treatment because your body is fighting you, and you need professional help to manage it.

SGLT2 inhibitors improve cardiovascular outcomes in heart failure patients, including those with preserved and reduced ejection fraction, independent of diabetes status.

If you have heart failure, ask your doctor about SGLT2 inhibitors. They are now recommended for heart failure patients regardless of whether they have diabetes, as they significantly improve outcomes.

Exposure to aerial environmental stressors, specifically fine particulate matter (PM2.5) and gaseous pollutants, causes cardiovascular disease and mortality through systemic inflammation, oxidative stress, and autonomic nervous system imbalance.

Monitor local air quality indices (AQI) and smog alerts. On days with high pollution, limit prolonged outdoor exertion, especially near traffic. Consider using air purifiers indoors and keeping windows closed during peak pollution times. This is a modifiable risk factor that acts independently of your diet and exercise habits.

Resmetirom, a THR-β agonist, improves histologic features of MASLD, including resolution of steatohepatitis without worsening fibrosis and improvement in fibrosis stage, in patients with F1-F3 fibrosis.

Resmetirom is the first FDA-approved drug for MASH. In clinical trials, doses of 80mg or 100mg taken daily for 52 weeks significantly improved liver inflammation and fibrosis compared to placebo. It is an option for those with F1-F3 fibrosis.

Obesity is a chronic, highly heritable neurological disease driven by central nervous system regulation of satiety and reward, rather than solely a behavioral failure of willpower.

Obesity is a biological condition involving brain pathways that control hunger and reward, heavily influenced by genetics. This means it is not simply a failure of willpower. Effective management often requires addressing these biological drivers, potentially through medical therapies that target these specific pathways, rather than relying solely on lifestyle changes which may be insufficient for those with high genetic risk.

Nutritional supplementation alone does not improve mobility or physical function in older adults when compared to physical activity interventions.

Do not rely on supplements to keep you mobile. While a healthy diet is important, it does not replace the need for physical activity. Focus on exercise groups rather than buying supplements for mobility.

GLP-1 receptor agonists provide significant cardiovascular risk reduction in both diabetic and non-diabetic patients with established cardiovascular disease, a benefit that is significantly under-recognized by physicians, particularly for non-diabetic patients.

For patients with obesity and established cardiovascular disease, GLP-1 agonists offer significant cardiovascular risk reduction (20% reduction in MACE in non-diabetics). Prescribers should be aware of these benefits to ensure appropriate patient selection and counseling, regardless of diabetic status.

The gut pathobiont Bilophila wadsworthia acts as a glycine sink by metabolizing glycine via the glycine reductase pathway, thereby lowering circulating glycine levels and negatively impacting metabolic markers.

The presence of the gut bacteria Bilophila wadsworthia consumes glycine, reducing its beneficial effects. Vegan diets tend to reduce this bacteria, thereby increasing glycine. While probiotics targeting this specific bacteria are not yet standard, understanding this link highlights why microbiome composition matters for metabolic health.

Imaging-based body composition assessment (DXA, CT, or MRI) is required to demonstrate that weight loss from anti-obesity drugs is attributable to fat mass reduction rather than lean mass loss, as mandated by updated US FDA and Korean MFDS guidelines.

If you are taking anti-obesity medication, ask your provider about body composition analysis (DXA or CT) rather than relying solely on weight. This ensures your weight loss is coming from fat stores and not muscle tissue, which is critical for long-term metabolic health and is now a regulatory standard for drug approval.

DXA is the preferred imaging modality for anti-obesity drug trials due to its balance of low radiation, cost-effectiveness, and accessibility, although CT and MRI offer superior precision for visceral fat and muscle quality assessment.

For most obesity drug trials, DXA is the standard imaging tool because it is cheap, safe, and widely available. However, if detailed analysis of visceral fat or muscle quality (myosteatosis) is needed, CT or MRI may be used despite higher costs.

MASLD is an independent risk factor for cardiovascular disease, including heart failure (particularly HFpEF), atrial fibrillation, and atherosclerosis, driven by shared mechanisms like insulin resistance and inflammation.

If you have fatty liver disease (MASLD), you are at a significantly higher risk for heart problems, including heart failure and atrial fibrillation, even if your liver enzymes are normal. This risk is driven by the same metabolic issues that cause fatty liver. You need regular cardiovascular screening and aggressive management of blood pressure, cholesterol, and blood sugar to protect your heart.

GLP-1 receptor agonists are associated with gastrointestinal side effects (nausea, vomiting, diarrhea) and potentially increased risks of pancreatitis and thyroid cancer.

GLP-1 agonists commonly cause GI issues like nausea and diarrhea, especially when starting or increasing the dose. Serious but rare risks include pancreatitis and thyroid cancer. Monitor your health and report severe symptoms to your doctor.

BMI is a valid and necessary tool for population-level surveillance of adiposity and obesity risk, but its use in individual clinical treatment decisions is inappropriate without additional measures.

Use BMI as a general screening tool for population health, not as a definitive diagnosis for individuals. If you are concerned about your health, ask for a comprehensive assessment including metabolic markers, not just a weight-based calculation.

GLP-1 based therapies carry class-wide safety warnings including gastrointestinal effects, gallbladder events, pancreatitis risk, and a boxed warning for medullary thyroid carcinoma based on rodent data.

These medications work well but can cause nausea, vomiting, or other GI issues. Your doctor will start you on a low dose and slowly increase it to help your body adjust. If you have a family history of specific thyroid cancers, you cannot take these drugs.

Creatine supplementation does not significantly affect fat mass (FM), BMI, or body fat percentage (BFP) in the general population, although specific loading protocols with maintenance phases may lead to modest BFP reductions.

Do not take creatine expecting it to burn fat or change your body fat percentage. It will not significantly affect your fat mass or BMI. Its primary benefit is adding lean muscle mass when combined with resistance training.

Tight glycemic control (HbA1c ≤ 6.5%) in Type 2 Diabetes does not significantly reduce major cardiovascular events or all-cause mortality compared to standard control, and may increase mortality and hypoglycemia risk.

For Type 2 Diabetics, aiming for an A1c of 7% or slightly higher (if safe) is often as effective for heart protection as aiming for very low numbers (≤6.5%), while avoiding the risks of severe hypoglycemia and weight gain. Focus on overall cardiovascular risk management (blood pressure, lipids) rather than obsessing over ultra-tight glucose control, unless you are newly diagnosed with Type 1 Diabetes.